Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of prophylactic emicizumab versus no prophylaxis in hemophilia A without inhibitors
jRCT2080223290Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2016
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of emicizumab in hemophilia A (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Aug 2016; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2080223290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223290.